| 產(chǎn)品編號 | 422175 |
| 品牌 | Sigma |
| 測定 | ≥98% (HPLC) |
| 顏色 | white |
| 運輸 | ambient |
| 形式 | solid |
| 警告 | Toxicity: Irritant (B) |
| 分子量 | 402.44 |
| 溶解性 | 1 M NaOH: 40?mg/mL
DMSO: 5?mg/mL |
| 質(zhì)量水平 | 100 |
| 儲存溫度 | 2-8°C |
| 儲存條件 | OK to freeze
protect from light |
| MDL編號 | MFCD04974501 |
別名
L-165,041 - CAS 79558-09-1 - Calbiochem,Compound P, L165041, 4-[3-(2-Propyl-3-hydroxy-4-acetyl)phenoxy]propyloxyphenoxy-acetic acid, PPAR Agonist VIII, PPARα Agonist III, PPARγ Agonist VII
一般描述
A cell-permeable phenoxyacetic acid derivative that acts as a potent and selective peroxisome proliferator activator receptor δ (PPARδ) agonist (Ki = 6 nM for hPPAR δ and 730 nM for hPPARγ). Induces adipocyte differentiation in NIH-PPARδ cells at 500 nM. Also reported to raise total cholesterol in insulin-resistant db/db mice without altering glucose or triglyceride levels. Shown to increase uncoupling protein 3 (UCP3) gene expression in L6 myotubes. Also shown to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and the secretion of monocyte chemotactic protein-1 (MCP-1) in Eahy926 cells.
A cell-permeable phenoxyacetic acid derivative that acts as a potent and selective peroxisome proliferator activator receptor δ (PPARδ) agonist (Ki = 6 nM for hPPARδ and 730 nM for hPPARγ). Potently induces adipocyte differentiation in NIH-PPARδ cells at 500 nM and raises total cholesterol in insulin resistant db/db mice without altering glucose or triglycerides levels. Increases UCP3 (uncoupling protein 3) gene expression in L6 myotubes. Inhibits cytokine-induced expression of VCAM-1 (vascular cell adhesion molecule-1) and the secretion of MCP-1 (monocyte chemotactic protein-1) in EAhy926 cells.
生化/生理作用
Cell permeable: yes
Primary Target
Peroxisome proliferator activator receptor δ (PPAR@delta;)
Product does not compete with ATP.
Reversible: no
Target Ki: 6 nM for hPPARδ and 730 nM for hPPARγ
重懸
Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
Rival, Y., et al. 2002. Eur. J. Pharmacol.435, 143.
Castrillo, A., et al. 2001. J. Biol. Chem.276, 34082.
Hansen, J.B., et al. 2001. J. Biol. Chem.276, 3175.
Son, C., et al. 2001. Endocrinology142, 4189.
Wilkie, N., et al. 2001. J. Neurochem.78, 1135.
Leibowitz, M.D., et al. 2000. FEBS Lett.473, 333.
Berger, J., et al. 1999. J. Biol. Chem.274, 6718.
Lim, H., et al. 1999. Genes Dev.13, 1561.
關(guān)鍵字： L-165,041 - CAS 79558-09-1 - Calbiochem;L-165,041 - CAS 79558-09-1 - Calbiochem價格;L-165,041 - CAS 79558-09-1 - Calbiochem廠家;79558-09-1;Sigma
關(guān)于默克生命科學(xué)
我們擁有廣泛的高質(zhì)量產(chǎn)品組合和解決方案，致力于推動科學(xué)研究，提高藥物研發(fā)和生物制藥生產(chǎn)的質(zhì)量和效率，并為獲取準(zhǔn)確可靠的診斷和檢測結(jié)果提供安全的保障。我們的愿景是使全球各地的人們能夠更快地獲得提升人類健康水平的解決方案。我們的共同目標(biāo)是通過與全球科學(xué)界合作，解決生命科學(xué)中棘手的問題。
30萬個廣泛產(chǎn)品組合，其中包括業(yè)內(nèi)許多知名的品牌，Sigma-Alrdich?、Milli-Q?、 Supelco?、Millipore?、SAFC?和BioReliance?。
關(guān)于默克
是一家全球領(lǐng)先的科技公司，專注于醫(yī)藥健康、生命科學(xué)和電子科技三大領(lǐng)域。全球約有57,000名員工服務(wù)于默克，通過創(chuàng)造更加愉悅和可持續(xù)性的生活方式，為數(shù)百萬人的生活帶來積極的影響。從先進的基因編輯技術(shù)和發(fā)現(xiàn)治療最具挑戰(zhàn)性疾病的獨特方法，到實現(xiàn)設(shè)備的智能化——默克無處不在。
科學(xué)探索和負(fù)責(zé)任的企業(yè)精神一直是默克科技進步的關(guān)鍵，也是默克自1668年以來永葆活力的秘訣。默克家族作為公司的創(chuàng)始者至今仍持有默克大部分的股份，我們在全球都叫“默克”，僅美國和加拿大例外。默克的三大領(lǐng)域：醫(yī)藥健康、生命科學(xué)及電子科技在這兩個國家分別稱之為“EMD Serono”、“MilliporeSigma”和“EMD Electronics”。
默克在中國已經(jīng)有87年發(fā)展歷史，目前有超過4100名員工，在